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The role of nutritional status as key factor of successful aging is very well recognized. Among the different mechanisms by which
nutrients may exert their beneficial effects is the modulation of the hormonal anabolic milieu, which is significantly reduced with
aging. Undernutrition and anabolic hormonal deficiency frequently coexist in older individuals determining an increased risk
of mobility impairment and other adverse outcomes. Mineral assessment has received attention as an important determinant of
physical performance. In particular, there is evidence that magnesium exerts a positive influence on anabolic hormonal status,
including Testosterone, in men. In this review we summarize data from observational and intervention studies about the role of
magnesium in Testosterone bioactivity and the potential underlying mechanisms of this relationship in male subjects. If larger
studies will confirm these pivotal data, the combination of hormonal and mineral replacements might be adopted to prevent or
delay the onset of disability in the elderly.
1. Biological Role of Magnesium
Magnesium is an essential ion involved in multiple fun-
damental physiologic functions in humans [1]. As part of
the activated MgATP complex, magnesium is involved in
the pathways generating adenosine triphosphate (ATP) and
energy in mitochondria, electron transport chain and com-
plex subunits, and oxygen detoxification. Magnesium is also
a cofactor in over 300 enzymatic reactions and biological
processes, including protein and nucleic acid synthesis, and
neuromuscular excitability [1].
Circulating magnesium exists in three forms. The
metabolically active free ionized fraction (magnesium ion)
is the most represented, accounting up to 60–70% of the
total serummagnesium.Othermain serum forms include the
protein-bound (25% and 8% bound to albumin and globulin,
resp.) and the chelated magnesium fraction (12%) [2].
The most represented reservoir of magnesium in human
body is the mineral phase of the bone that accounts for
about 64% of total magnesium. The remaining amount is
located in the intracellular (34%) and extracellular spaces
(1%). The intracellular magnesium concentration is funda-
mental to ensure the most important cellular and metabolic
activities [3]. Indeed, the rapid requirements of this cation are
usuallymet by intracellular stores thatmore quickly exchange
magnesium with intracellular fluids.
Because of the lack of clinical tests available for assessing
total-body magnesium content, the serum magnesium con-
centration remains the most clinically reliable test.
Adequate serummagnesium levels (normal ranges: 0.75–
0.95mmol/L or 1.7–2.5mg/dL) seem to be critical in ensuring
the normal cellular homeostasis [1, 2]. Magnesium status is
influenced by dietary intake, absorption in the gastrointesti-
nal tract, renal excretion, and tissue uptake and utilization
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(e.g., cardiac and skeletal muscle tissue) [4]. To guarantee an
optimal magnesium homeostasis the recommended intake
from dietary sources is estimated in 420 and 320mg/day
for healthy men and women, respectively [5]. Food-rich
magnesium sources are cereals, green leafy vegetables, seeds,
nuts, cocoa, and seafood [6]. However, the definition of
magnesium deficiency is notoriously complex. Magnesium
serum concentrations below the laboratory reference range
of <1.8mg/dL are currently used to define some degree
of magnesium depletion. However, this cut-off value could
be not necessarily related to a pathophysiologic state of
deficiency, because low intracellular magnesium has been
documented even in patients with serum magnesium con-
centrations >1.8mg/dL [7].
2. Magnesium and Muscle Function in
Young Trained Individuals
Magnesium has been the most investigated mineral involved
in muscle function. The beneficial effects of magnesium on
skeletal muscle and physical performance are linked to its
known actions on energetic metabolism (phosphorylation
processes and reactions requiring ATP, energy utilization
and transfer, and transmembrane transport) which have
enormous implications in muscle contraction [1]. In fact,
dietary magnesium deprivation is associated with increased
oxygen requirements to complete submaximal exercise and
reduced endurance performance [8].
Magnesium administration elicited the reductions in
heart rate, ventilation, oxygen uptake, and carbon diox-
ide production during submaximal work [9, 10]. In male
athletes, 25 days of magnesium (390mg/d), with a 3wk
washout, increased peak oxygen uptake and total work
output during work capacity tests [11]. Similarly, in physi-
cally active collegians, magnesium supplementation signif-
icantly improved endurance performance and oxygen uti-
lization [12]. In a depletion-repletion experiment in 10 post-
menopausal women (aged 45–71), dietary magnesium (320
versus 180mg/d) improved magnesium balance, erythrocyte
and skeletal muscle magnesium concentrations, heart rate,
and oxygen consumption during submaximal exercise [13].
It is not surprising that most of the current observational
and intervention studies have been conducted on athlete
subjects. In young men participating at 7-week strength
training program, supplemental magnesium was capable of
significantly improving muscle strength and power [14]. The
gain in muscle strength occurred at dietary magnesium
intake higher than 250mg/d and was even more evident at
500mg/d (exceeding the recommended dietary allowance,
RDA) [14]. However, magnesium supplementation per se
does not affect work performance in magnesium-replete
trained individuals [15]. Dietary surveys reveal a magnesium
intake equaling or exceeding the RDA for male athletes [16].
In female athletes it tends to be 60% to 65% of the current
recommendation. Regardless of sex, athletes competing in
sports requiringweight classifications or esthetic components
tend to consume up to 30–55% of the magnesium RDA
[17]. Serum magnesium levels may also be reduced during
intense and/or long-term exercise [18] leading to latent
fatigue and decreased endurance [19], similarly to what has
been observed during the condition of zinc deficiency [20].
These lines of evidence led to consider magnesium as
potentially limiting element for human physical perfor-
mance, creating the rationale for the routine use of magne-
sium supplementation during intense endurance exercise.
3. Age-Related Changes in Magnesium
Levels and Physical Performance
Suboptimalmagnesium status is a frequent condition in older
persons.Themost common cause of magnesium deficit is the
low dietary magnesium intake [21].This is a well-represented
phenomenon in older population, occurring in up to 10–
15% of community-dwelling older subjects [22]. The typical
western diet, highly rich in processed foods and deficient in
green vegetables and whole grain, may also contribute to an
inadequate magnesium intake.
The magnesium requirement for older population does
not differ from young and adult subjects. However, data
from the National Health and Nutrition Examination Survey
(NHANES) III show an average daily magnesium intake
dramatically below the recommendedRDA, approximately of
225mg/day in men and 166mg/day in women [5].
A suboptimal magnesium status may also result from
altered magnesium absorption and/or increased urinary
loss [23]. Polypharmacotherapy (loop diuretics, digitals, and
proton pump inhibitors) as well as a wide range of clinical
conditions (HIV, type 2 diabetes, alcoholism, and cardiovas-
cular diseases) plays additional important roles in lowering
magnesium levels [24–26].
However, themagnesiumdeficiency ismore difficult to be
detected in the elderly population. In fact the pauperization
of intracellular stores is not usually accompanied by a parallel
decline in magnesium serum concentrations that tend to
remain more stable, within the normal range [27]. The
deficiency of magnesium at cellular level and in the body
stores is crucial formaintaining the skeletal muscle efficiency.
It is very well known that sarcopenia (recently defined by
consensus documents as the presence of both low muscle
mass and low muscle function (strength or performance))
[28–30] frequently leads to a condition of decreased phys-
iological reserve, increased vulnerability to stressors, and
adverse outcomes, known as “frailty” [31]. The frail status is
a strong predictor of mortality, independent of traditional
indicators of disease [32]. Despite the role of magnesium
in muscle integrity and function, there are few data in this
regard in the elderly. In a representative cohort of 1138 older
men, Dominguez and colleagues [33] using data from the
InCHIANTI Study showed a significant, independent, and
strong positive relationship between circulating magnesium
levels and measures of muscle performance (hand grip
strength, lower-leg muscle power, knee extension torque,
and ankle extension strength). These authors suggested the
need of identifying serummagnesium cut-off values to attain
the best possible physical function. These data suggest the
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potential contribution of low magnesium status, frequently
observed in the elderly, to the reduced physical performance.
4. The Concept of Nutritional Modulation of
Anabolic Hormonal Status in Older Men
In healthy adult subjects, changes in food consumption
and utilization may induce homeostatic adaptations that
redistribute nutrients without affecting muscle function and
physical performance. During the aging process the body
energy delivery system could be impaired because of the
decline in physiological reserves and the disruption of
metabolic pathways, and sarcopenia may arise. Physiological,
psychological, and hormonal systems interact to determine
the energy need. Macronutrients are essential to provide the
body structure to perform work. Minerals are fundamental
to enable the use of macronutrients for all physiological
processes. In fact, an insufficient qualitative and quantitative
nutrient intake is one of the multiple causes of loss of
muscle mass, decreased physical performance, and adverse
outcomes [34]. Anabolic hormones, whose levels decrease
with age, play an important role in maintaining the optimal
body energy delivery. In older persons, the occurrence of a
single mild hormonal derangement is rarely observed. More
frequently there is a simultaneous anabolic hormonal defi-
ciency [Testosterone (T), Dehydroepiandrosterone (DHEA),
estradiol (E2), growth hormone-Insulin-like Growth Factor-
1 (GH-IGF-1), and vitamin D] which is part of “multiple
hormonal dysregulation” [35]. These hormones interplay in
ensuring overall anabolic state and induce the satellite cell
activation together with exercise and muscle hypertrophy
[35].The simultaneous presence of low levels of Testosterone,
together with DHEAS and IGF-1, has a strong effect on all-
cause mortality in older men [36]. Experimental data con-
firm that hormonal therapies, singularly or in combination,
may improve body composition and physical performance
[37–41]. The nutrients (especially the minerals magnesium,
selenium, and zinc) and the anabolic hormones, especially T
and IGF-1, seem to interact. The combination of nutritional
and hormonal strategies in frail undernourished older people
determines a more effective reduction in the number of
hospitalizations, the time to hospital admission, and the
days of hospital stay [42, 43]. The specific actions of both
micronutrients andhormones at skeletalmuscle level have led
to the hypothesis of an interaction of these factors in ensuring
optimal physical performance [44].This novel concept could
have important clinical implications in the elderly, who
are more prone to a disruption of the anabolic/catabolic
equilibrium and undernutrition. The use of specific mineral
supplements may represent a sort of preventive measure of
mobility impairment.
5. Changes in Testosterone Secretion
with Age and Implications in Skeletal
Muscle Function
Testosterone is the most important male sex steroid, synthe-
sized by the Leydig cells of the testes (95%) and derived by
peripheral adrenal androgens conversion for the remaining
5% [45].
In men, up to 44–65% of the circulating plasma T is
bound to sex hormone binding globulin (SHBG) and 33–
54% to albumin, and approximately 2-3% is available as a free
form. The free fraction of circulating T plus albumin-bound
T represents the amount of biologically active T (Bio-T) that
more accurately reflects the clinical androgen state of the
subject [46]. Total T levels progressively decrease from the age
of 35, by 1% per year.The decline is more pronounced for Bio-
T, 2%per year [45], especially in untreated depressedmen [47,
48].The causes of the age-related fall in total and Bio-T levels
include a decrease in testicular function and a disruption of
hypothalamic-pituitary axis. This peculiar phenomenon of
the ageing process involves the GnRH secretion and activity
(reduced amplitude of the peaks, attenuation of the circadian
rhythm, and reduced sensitivity to negative feedback), the
pituitary gland (reduced gonadotropin response to GnRH),
and the Leydig cells (reduced response to human chorionic
gonadotropin, HCG) [49].
Other mechanisms such as the increased SHBG lev-
els and T aromatization (increased activity aromatase in
adipose tissue) as well as the reduced bioconversion of
T into dihydrotestosterone could also concur to impair T
biological activity with age [50, 51]. Some authors hypothesize
that the age-related decline in androgenic activity could
be related to the reduced DHEA secretion, which is an
important precursor of T [52]. Finally, qualitative changes
in signaling transduction (reduced T receptors expression
and/or impaired T binding capacity in the liver, brain, and
prostate) should be also accounted for [53, 54].
The anabolic, anticatabolic, and neurotrophic effects of
T administration on muscle are well known and extensively
studied.
Observational studies on castrated animals [55] and adult
men [56, 57] show that low T levels are associated with a
reduction in lean body mass and muscle strength and other
negative changes in body composition.
In a very recent cross-sectional analysis of 250 patients, 70
years or older, Ucak et al. [58] have found a negative impact
of “compensated” or “subclinical” hypogonadism (defined
as mild biochemical alterations accompanied by signs and
symptoms of T deficiency) [59] on physical function, mood,
cognitive, and nutritional status.
Intervention studies on elderly subjects have documented
beneficial effects of T on counteracting the age-related
changes of body composition and physical function [60–62].
T exerts direct influence on lean body mass and strength
[63, 64], whereas equivocal evidence is available on the effects
of T on physical performance and quality of life [35].
The anabolic effects of T are even more evident in older
subjects with mobility limitation.
In 209 community-dwelling men with low T levels (100
to 350 ng/dL [3.5 to 12.1 nmol/L]) from Testosterone in Older
Men (TOM) with Mobility Limitations Trial, the daily T
gel therapy for 6 months improved both leg-press and
chest-press strength and stair-climbing power [65]. Testos-
terone may also influence muscle metabolism by improving
haemoglobin levels in older men with mild anaemia [66, 67].
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In women, skeletal muscle tissue seems to be sensitive to the
anabolic action of androgens [68]. However, the impact of T
administration on full physical function has not been fully
studied.The precise molecular mechanisms underlying these
observed physical changes inmen are likely to include specific
T effects on adipocytes and skeletal muscle cell receptors.The
binding of T to its receptors could lead to the stimulation of
lipolysis and protein synthesis [41, 69]. Finally, several lines
of evidence support the hypothesis of permissive effects of
T on the differentiation of the precursor stromal cells into
muscular line [70].
6. The Interplay between Magnesium and
Testosterone in Physical Function
The hypothesis of a link between magnesium and T has
been tested in pivotal experiences using magnesium supple-
mentation in adult subjects. Brilla and Conte investigated
the combined role of magnesium supplementation and exer-
cise on T levels [71]. A simple zinc-magnesium nutritional
formulation (30mg zinc monomethionine aspartate, 450mg
magnesium aspartate, and 10.5mg of vitamin B-6) was
able to improve T levels of athletes engaging in intense
physical activity compared to placebo (132.1 to 176.3 pg/mL
versus 141 to 126.6 pg/mL). The highest levels of T were
found in those athletes both exercising and receiving mag-
nesium supplementation. Moreover, significant differences
in muscle strength via torque measurements and functional
power were noted between the 2 groups (189.9 to 211 Nm
at 180∘/s and 316.5 to 373.7Nm at 300∘/s versus 204.2 to
209.1 Nm at 180∘/s and 369.5 to 404.3Nm at 300∘/s). These
data have been confirmed in a recent study performed on
young subjects, where 4-week magnesium supplementation
(magnesium sulfate 10mg/kg/d) and exercise increase free
and total T concentrations at exhaustion before and after
supplementation compared to resting levels [72, 73].There are
limited data about the relationship between magnesium and
T in study population, especially of older subjects. Maggio
and colleagues [74] in 399 older men ≥ 65 years (74.18 ±
6.43 mean age ± SD) from the InCHIANTI Study docu-
mented for the first time the strong and positive association
between magnesium levels and total T and total IGF-1 levels.
Interestingly, the relationship between magnesium and T
was independent of body mass index, IL-6, DHEAS, SHBG,
insulin, total IGF-1, grip strength, Parkinson’s disease, and
chronic heart failure. Because of the cross-sectional nature
of the study the authors could not establish a cause-effect
relationship between magnesium and T levels. This finding
led the authors to perform a pilot single-center, random-
ized, placebo-controlled, single-blind intervention study. 46
elderly hospitalizedmale subjects (21 in the treatment group),
aged 65 years or older, with magnesium serum levels <
2.5mg/dL, were randomly assigned to magnesium sulfate
treatment (1 g/mL of ion Mg++ diluted in 250 cc of normal
saline solution) or placebo (250 cc of saline solution) [75].
The active product or placebo was in a single intravenous
dose administered in about 30 minutes. Testosterone, IGF-
1, SHBG, and C-reactive protein (CRP) concentrations were
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Figure 1: Changes in Testosterone levels at baseline and after
treatment. Changes in the average Testosterone levels (nmol/L)
before (baseline) and after (post-treatment) magnesium sulfate
administration (blue line) and placebo (red line). The difference in
total Testosterone levels between the 2 groups touched the statistical
significance (𝑃 = 0.12).
evaluated before and after treatment. All measurements were
performed at the Laboratory of the University-Hospital of
Parma. Baseline characteristics between intervention and
control groups were analyzed by 𝑡-test. Paired 𝑡-test was used
to examine and to compare the response trends between the
two groups at baseline and after treatment. As expected, mag-
nesium sulfate administration induced a significant increase
in serum magnesium levels (delta 1.28 ± 0.61) compared
to placebo (delta −0.03 ± 0.14) (𝑃 < 0.001). Interestingly,
total T levels remained substantially unchanged (delta 0.01 ±
0.80) in the intervention group while they were significantly
decreased in the placebo group (delta −0.03 ± 0.14). The
difference in total T levels between the 2 groups touched the
statistical significance (𝑃 = 0.12) (Figure 1). No differences
were appreciated in bioavailable T (Bio-T), IGF-1, and SHBG
concentrations. In this preliminary analysis no differences in
CRP levels were observed between the two groups at baseline.
The adjustment for CRP levels at baseline did not affect the
relationship between magnesium and total T [75].
These preliminary data in humans are supported by
experimental studies in animal models.
Interestingly, magnesium supplementation has been
shown to have an apparent beneficial effect on male gonadal
system, as observed in a very recent study performed on
sexually mature male rats [76]. Chandra et al. evaluated the
morphological, cytological, and functional changes in testis
after magnesium administration. Interestingly, the authors
showed significant enhancing in steroidogenic enzymes,
namely, delta(5)3beta-hydroxysteroid dehydrogenase and
17beta-hydroxysteroid dehydrogenase, activities at moderate
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Figure 2: Relationship between Testosterone and magnesium, potential underlying mechanisms and clinical implications.The aging process
is frequently characterized by an impaired homeostatic reserve due to an imbalance between energy assumption (left side) and utilization
and consumption (middle and right sides). The activity of anabolic hormones, where T plays a central role, is influenced by mineral status
(magnesium), along with caloric and protein intake.The systemic inflammation, which negatively influences magnesium and T and is in turn
downregulated by these 2 factors.
and high dose of magnesium that resulted in increased
serum T levels [76]. This phenomenon was followed by a
progressive development in cytoarchitecture of genital organs
without significant changes in quantitative spermatogenesis.
The results were remarkably more evident in the groups
treated for a longer period and at high doses of magnesium.
In mice, dietary magnesium depletion seems to target api-
cal cells within caput epididymis [77]. Moreover, in older
male dromedary camel, the age-related decline in plasma T
concentrations has been associated with a disruption of the
mechanisms controlling normal cation distribution (includ-
ing magnesium) in the testis, epididymis, and accessory
glands [78].
7. The Role of Inflammation in
the Interplay between Magnesium and
Testosterone Levels
We can account for different factors influencing both T
and magnesium concentration in adult and elderly men.
Particular attention deserves the role of inflammation, which
is a negative modulator of both these factors.
Inflammatory cytokines act as inhibitory factors at pitu-
itary (on the secretion of LH) and testicular level (reduction
of T secretion and sensitivity of T to LH) [79], contributing
to the development of hypogonadism.
Higher levels of inflammatory markers and low T con-
centration are strong predictors of frailty, disability, and
cardiovascular events [80, 81] that negatively influence the
muscle mass [82].
In oldermen, there is a steeper decline of T levels during a
proinflammatory postoperative status (also known as “acute
postoperative frailty”) [83].
However, short-term T administration seems in turn
to reduce systemic inflammatory cytokines including TNF-
alpha, IL-6, and IL-1𝛽 [84] and to increase the anti-
inflammatory cytokine IL-10 [85]. In a similar manner,
magnesium seems to be fundamental in maintaining the
threshold of antioxidant capacity and the control of oxida-
tive stress [1]. Moreover, there is evidence of impaired
overall antioxidant capacity and low-grade inflammation in
magnesium-deficient cultured human and animals cells [86].
Inadequate intracellular magnesium may reduce the mito-
chondrial efficiency and increase the production of reactive
oxygen species (ROS), determining structural and functional
impairment of proteins [87] and DNA [88]. Interestingly,
magnesium and T were found to be lower during systemic
inflammation, and conditions associated with both increased
ROS, oxygen-derived free radicals, oxygen peroxide pro-
duction, and impaired antioxidant enzyme expression and
activity [89, 90].
Multiple changes in physiological pathways could be
identified as pathogenic factors in several age-related phe-
nomena including sarcopenia, frailty, disability, or altered
immune response and chronic diseases. Therefore, during
the aging process, where lower anabolic hormones, increased
proinflammatory cytokines, and impaired nutritional status
frequently coexist, combined strategies could have important
clinical implications [91] (Figure 2).
8. Biomolecular Mechanisms
Underlying the Relationship between
Magnesium and Testosterone
In the recent years biomolecular interactions between T,
SHBG, and magnesium have been studied by high perfor-
mance liquid chromatography (HPLC) [92]. Excoffon and
colleagues [92] provided evidence of a magnesium-mediated
variation in the T-SHBG affinity. The change in magnesium
levels inside the biological serum concentration range (0.75–
0.95mM) could lead to an enhancement of the Bio-T. In
fact, the affinity of T to SHBG seems to change slightly with
the magnesium concentration. Magnesium binds SHBG in
a nonspecific mode, leading to an uncompetitive inhibition
6 International Journal of Endocrinology
with T in binding SHBG and to a subsequent enhancement
of Bio-T availability. The binding is accompanied by a
magnesium release (or uptake) with a corresponding heat
effect around in magnitude 17 kJ/mol [92].
SHBG is a homodimer comprising 373 amino acid
residues for each monomer that transports the sex steroids in
the blood and also regulating their activity in target cells [93].
Interestingly, each monomer of SHBG contains three metal-
binding sites, one calcium-binding and two zinc-binding,
[94, 95], that are divalent cations as well as magnesium. This
data supports, at molecular level, the role of magnesium in
modulating T bioactivity.
Guillaume’s group investigated the role of magnesium
on both the T-serum albumin binding process and the T
displacement to its human serum albumin (HSA) binding
cavity by DHEA. Serum albumin binds to T with low affinity
[46]. In particular DHEA and T seem to bind to the same
HSA site. DHEA has been shown to displace T to its HSA
binding site. The authors observed in vitro that adequate
magnesium concentrations displaced T from itsHSA binding
site [96, 97] and hypothesized the opportunity of testing
in vivo the effects of magnesium supplementation, during
DHEA treatment, on the Bio-T rate.
9. Conclusions
The ageing process seems to be at least partly due to
the defect of anabolic hormones, low-grade inflammation,
reduced physical activity, and a poor quality of nutrition.The
permissive role that several micronutrients, such as mag-
nesium, might exert on the serum concentration and the
biological activity of T could be of undoubted interest for
future clinical approaches. Male individuals with impaired
magnesium status and T deficiency (accurately assessed)
could benefit from magnesium and/or T treatment target-
ing physical performance. Future randomized clinical trials
adopting synergistic treatments could lead to improving the
effectiveness of T treatment, in preventingmobility limitation
and adverse outcomes in older men.
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